Wealthspire Advisors (New York)’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
Other funds holding BIIB
Wealthspire Advisors (New York)'s BIIB Position: Q2 2026 in Review
Wealthspire Advisors (New York) increased its Biogen (BIIB) stake by 33% in Q2 2026, buying an estimated $76.1K and bringing the position to 1,607 shares worth $347K. The position accounts for ﹤0.01% of the portfolio, ranked #941.
Wealthspire Advisors (New York) first reported a position in BIIB in Q4 2018 and has held it in 19 quarters since. The position peaked at $1.09M in Q1 2020. 1,046 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Wealthspire Advisors (New York) held 1,607 shares of Biogen worth $347K as of Q2 2026.
- Wealthspire Advisors (New York) bought 398 Biogen shares in Q2 2026, an estimated $76.1K.
- Biogen made up ﹤0.01% of Wealthspire Advisors (New York)'s portfolio in Q2 2026, its #941 holding.
- Wealthspire Advisors (New York) first reported a position in Biogen in Q4 2018 and has held it in 19 quarters since.
- Wealthspire Advisors (New York)'s Biogen position peaked at $1.09M in Q1 2020.
- 1,046 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Wealthspire Advisors (New York)'s 13F filing for Q2 2026, filed 11 Aug 2026.